12:00 AM
 | 
Sep 24, 2012
 |  BC Week In Review  |  Company News  |  Deals

Dyax, Kadmon deal

Dyax granted Kadmon exclusive, worldwide development and commercialization rights for DX-2400. Dyax will receive an undisclosed upfront payment and is eligible for milestones, plus...

Read the full 106 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >